Skip to main content
SpringerLink
Log in

Cancer Treatment-Related Cardiotoxicity: Role of Cardiovascular Magnetic Resonance Imaging

  • Chapter
  • First Online:
Cancer and Cardiovascular Disease

  • 586 Accesses

Abstract

Cardiomyopathy is one of the most common cardiotoxic manifestations from cancer treatment. Clinically, identifying the presence or absence of cardiomyopathy has significant implications on the management of cancer patients. Decisions regarding the continuation, temporary stopping or permanent stopping of potentially life-saving cancer treatment are made based on the presence or absence of, the etiology of (i.e., whether it is a consequence of the cancer treatment or unrelated), and the severity of cardiomyopathy. Thus, it is critically important to use an imaging test that can reliably and accurately provide these data. Cardiovascular magnetic resonance (CMR) is ideally suited for this role—it provides the ability to assess ventricular function, morphology, valvular function, perfusion and tissue characterization all in one setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387–96.

    Article  CAS  PubMed  Google Scholar 

  2. Farber NJ, Reddy ST, Doyle M, et al. Ex vivo cardiovascular magnetic resonance measurements of right and left ventricular mass compared with direct mass measurement in excised hearts after transplantation: a first human SSFP comparison. J Cardiovasc Magn Reson. 2014;16:74.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30:2876–84.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Neilan TG, Coelho-Filho OR, Pena-Herrera D, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012;110:1679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Huang H, Nijjar PS, Misialek JR, et al. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017;19:34.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Pennell DJ. Cardiovascular magnetic resonance. Circulation. 2010;121:692–705.

    Article  PubMed  Google Scholar 

  7. Ylanen K, Poutanen T, Savikurki-Heikkila P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013;61:1539–47.

    Article  PubMed  Google Scholar 

  8. Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 2013;168:5465–7.

    Article  PubMed  Google Scholar 

  9. Calleja A, Poulin F, Khorolsky C, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy. J Oncol. 2015;2015:609194.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Christiansen JR, Massey R, Dalen H, et al. Right ventricular function in long-term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. Eur Heart J Cardiovasc Imaging. 2016;17:735–41.

    Article  PubMed  Google Scholar 

  11. Boczar KE, Aseyev O, Sulpher J, et al. Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. Echo Res Pract. 2016;3:79–84.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Murbraech K, Holte E, Broch K, et al. Impaired right ventricular function in long-term lymphoma survivors. J Am Soc Echocardiogr. 2016;29:528–36.

    Article  PubMed  Google Scholar 

  13. Abdar Esfahani M, Mokarian F, Karimipanah M. Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy. Postgrad Med J. 2017;93:271–4.

    Article  PubMed  Google Scholar 

  14. Ostenfeld E, Flachskampf FA. Assessment of right ventricular volumes and ejection fraction by echocardiography: from geometric approximations to realistic shapes. Echo Res Pract. 2015;2:R1–11.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Senthilkumar A, Majmudar MD, Shenoy C, Kim HW, Kim RJ. Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance. Heart Fail Clin. 2009;5:349–67, vi.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.

    Article  CAS  PubMed  Google Scholar 

  17. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303–71.

    Article  PubMed  Google Scholar 

  18. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.

    Article  CAS  PubMed  Google Scholar 

  19. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol. 2008;52:148–57.

    Article  PubMed  Google Scholar 

  21. Kitkungvan D, Nabi F, Ghosn MG, et al. Detection of LA and LAA thrombus by CMR in patients referred for pulmonary vein isolation. JACC Cardiovasc Imaging. 2016;9:809–18.

    Article  PubMed  Google Scholar 

  22. Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6:1080–91.

    Article  PubMed  Google Scholar 

  23. Jordan JH, Vasu S, Morgan TM, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging. 2016;9:e004325.

    Google Scholar 

  24. Jordan JH, D’Agostino RB Jr, Hamilton CA, et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2014;7:872–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Melendez GC, Hundley WG. Is myocardial fibrosis a new Frontier for discovery in cardiotoxicity related to the administration of anthracyclines? Circ Cardiovasc Imaging. 2016;9:e005797.

    Article  PubMed  Google Scholar 

  26. Drafts BC, Twomley KM, D’Agostino R Jr, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–85.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Chaosuwannakit N, D’Agostino R Jr, Hamilton CA, et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28:166–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Medicine, University of Minnesota Medical Center, 420 Delaware Street SE, MMC 508, Minneapolis, MN, 55455, USA

    Felipe Kazmirczak & Chetan Shenoy

  2. Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA

    Prajwal Reddy

  3. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, 420 Delaware Street SE, MMC 508, Minneapolis, MN, 55455, USA

    Anne H. Blaes

Authors
  1. Felipe Kazmirczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prajwal Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne H. Blaes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chetan Shenoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chetan Shenoy .

Editor information

Editors and Affiliations

  1. Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Syed Wamique Yusuf

  2. Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Jose Banchs

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Kazmirczak, F., Reddy, P., Blaes, A.H., Shenoy, C. (2018). Cancer Treatment-Related Cardiotoxicity: Role of Cardiovascular Magnetic Resonance Imaging. In: Yusuf, S., Banchs, J. (eds) Cancer and Cardiovascular Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-62088-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62088-6_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62086-2

  • Online ISBN: 978-3-319-62088-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation